论文部分内容阅读
目的观察优泌乐50治疗口服降糖药不达标的2型糖尿病患者的临床疗效。方法 72例口服降糖药物不达标的2型糖尿病患者,随机分为研究组和对照组,各36例。研究组应用优泌乐50控制血糖治疗;对照组应用诺和锐30控制血糖治疗。比较两组患者控制血糖的疗效及低血糖发生率。结果 3个月后疗效:研究组患者在餐后2 h血糖、糖化血红蛋白方面明显优于对照组,差异有统计学意义(P<0.05);两组患者在空腹血糖、胰岛素用量、低血糖发生率方面比较差异无统计学意义(P>0.05)。结论 3次/d皮下注射优泌乐50治疗口服降糖药失效的2型糖尿病临床疗效好,餐后血糖控制满意,低血糖反应无增加,值得临床推广应用。
Objective To observe the clinical efficacy of Uehara 50 in treating patients with type 2 diabetes who do not achieve oral hypoglycemic agents. Methods A total of 72 patients with type 2 diabetes who did not receive oral glucose-lowering drugs were randomly divided into study group and control group, with 36 cases in each group. Study group gifted secrete 50 blood glucose control; control group norvo Rui 30 blood sugar control. The curative effect of controlling blood sugar and incidence of hypoglycemia in two groups were compared. Results 3 months after treatment: the study group patients 2h postprandial blood glucose, glycosylated hemoglobin was significantly better than the control group, the difference was statistically significant (P <0.05); two groups of patients in the fasting blood glucose, insulin dosage, hypoglycemia The difference was not statistically significant (P> 0.05). Conclusion 3 times / d subcutaneous injection of gose Le 50 treatment of oral hypoglycemic failure type 2 diabetes clinical efficacy, satisfaction with postprandial blood glucose control, no increase in hypoglycemic response, worthy of clinical application.